Your browser doesn't support javascript.
Trends in Severe Outcomes Among Adult and Pediatric Patients Hospitalized With COVID-19 in the Canadian Nosocomial Infection Surveillance Program, March 2020 to May 2022.
Mitchell, Robyn; Cayen, Joelle; Thampi, Nisha; Frenette, Charles; Bartoszko, Jessica; Choi, Kelly Baekyung; Comeau, Jeannette L; Conly, John; Ellis, Chelsey; Ellison, Jennifer; Embil, John; Evans, Gerald; Johnston, Lynn; Johnstone, Jennie; Katz, Kevin C; Kibsey, Pamela; Lee, Bonita; Lefebvre, Marie-Astrid; Longtin, Yves; McGeer, Allison; Mertz, Dominik; Minion, Jessica; Rudnick, Wallis; Silva, Anada; Smith, Stephanie W; Srigley, Jocelyn A; Suh, Kathryn N; Tomlinson, Jen; Wong, Alice; Pelude, Linda.
  • Mitchell R; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
  • Cayen J; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
  • Thampi N; Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
  • Frenette C; Division of Infectious Diseases, Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.
  • Bartoszko J; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
  • Choi KB; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
  • Comeau JL; Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Conly J; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Ellis C; Department of Laboratory Medicine, The Moncton Hospital, Moncton, New Brunswick, Canada.
  • Ellison J; Infection, Prevention and Control, Alberta Health Services, Calgary, Alberta, Canada.
  • Embil J; Infection Prevention and Control, Health Sciences Centre, Winnipeg, Manitoba, Canada.
  • Evans G; Division of Infectious Diseases, Queen's University, Kingston, Ontario, Canada.
  • Johnston L; Division of Infectious Diseases, Department of Medicine, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada.
  • Johnstone J; Infection Prevention and Control, Sinai Health, Toronto, Ontario, Canada.
  • Katz KC; Infection Prevention and Control, North York General Hospital, Toronto, Ontario, Canada.
  • Kibsey P; Department of Pathology and Laboratory Medicine, Royal Jubilee Hospital, Victoria, British Columbia, Canada.
  • Lee B; Department of Pediatrics, Stollery Children's Hospital, Edmonton, Alberta, Canada.
  • Lefebvre MA; Montreal Children's Hospital, McGill University Health Centre, Montréal, Québec, Canada.
  • Longtin Y; Infection Prevention and Control, SMBD Jewish General Hospital, Montréal, Québec, Canada.
  • McGeer A; Infection Prevention and Control, Sinai Health, Toronto, Ontario, Canada.
  • Mertz D; Division of Infectious Diseases, Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada.
  • Minion J; Department of Laboratory Medicine, Saskatchewan Health Authority, Regina, Saskatchewan, Canada.
  • Rudnick W; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
  • Silva A; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
  • Smith SW; Faculty of Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada.
  • Srigley JA; Infection Prevention and Control, BC Women's and BC Children's Hospital, Vancouver, British Columbia, Canada.
  • Suh KN; Infection Prevention and Control, The Ottawa Hospital, Ottawa, Ontario, Canada.
  • Tomlinson J; Infection Prevention and Control, Health Sciences Centre, Winnipeg, Manitoba, Canada.
  • Wong A; Division of Infectious Diseases, Department of Medicine, Royal University Hospital, Saskatoon, Saskatchewan, Canada.
  • Pelude L; Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, Ottawa, Ontario, Canada.
JAMA Netw Open ; 6(4): e239050, 2023 04 03.
Artículo en Inglés | MEDLINE | ID: covidwho-2300176
ABSTRACT
Importance Trends in COVID-19 severe outcomes have significant implications for the health care system and are key to informing public health measures. However, data summarizing trends in severe outcomes among patients hospitalized with COVID-19 in Canada are not well described.

Objective:

To describe trends in severe outcomes among patients hospitalized with COVID-19 during the first 2 years of the COVID-19 pandemic. Design, Setting, and

Participants:

Active prospective surveillance in this cohort study was conducted from March 15, 2020, to May 28, 2022, at a sentinel network of 155 acute care hospitals across Canada. Participants included adult (aged ≥18 years) and pediatric (aged 0-17 years) patients hospitalized with laboratory-confirmed COVID-19 at a Canadian Nosocomial Infection Surveillance Program (CNISP)-participating hospital. Exposures COVID-19 waves, COVID-19 vaccination status, and age group. Main Outcomes and

Measures:

The CNISP collected weekly aggregate data on the following severe

outcomes:

hospitalization, admission to an intensive care unit (ICU), receipt of mechanical ventilation, receipt of extracorporeal membrane oxygenation, and all-cause in-hospital death.

Results:

Among 1 513 065 admissions, the proportion of adult (n = 51 679) and pediatric (n = 4035) patients hospitalized with laboratory-confirmed COVID-19 was highest in waves 5 and 6 of the pandemic compared with waves 1 to 4 (77.3 vs 24.7 per 1000 patient admissions). Despite this, the proportion of patients with positive test results for COVID-19 who were admitted to an ICU, received mechanical ventilation, received extracorporeal membrane oxygenation, and died were each significantly lower in waves 5 and 6 when compared with waves 1 through 4. Admission to the ICU and in-hospital all-cause death rates were significantly higher among those who were unvaccinated against COVID-19 when compared with those who were fully vaccinated (incidence rate ratio, 4.3 and 3.9, respectively) or fully vaccinated with an additional dose (incidence rate ratio, 12.2 and 15.1, respectively). Conclusions and Relevance The findings of this cohort study of patients hospitalized with laboratory-confirmed COVID-19 suggest that COVID-19 vaccination is important to reduce the burden on the Canadian health care system as well as severe outcomes associated with COVID-19.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Infección Hospitalaria / COVID-19 Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Adolescente / Adulto / Niño / Humanos País/Región como asunto: America del Norte Idioma: Inglés Revista: JAMA Netw Open Año: 2023 Tipo del documento: Artículo País de afiliación: Jamanetworkopen.2023.9050

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Infección Hospitalaria / COVID-19 Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Adolescente / Adulto / Niño / Humanos País/Región como asunto: America del Norte Idioma: Inglés Revista: JAMA Netw Open Año: 2023 Tipo del documento: Artículo País de afiliación: Jamanetworkopen.2023.9050